Published in:
Open Access
01-10-2020 | Myocarditis | Consensus Paper
Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology
Authors:
Tienush Rassaf, Matthias Totzeck, Johannes Backs, Carsten Bokemeyer, Michael Hallek, Denise Hilfiker-Kleiner, Andreas Hochhaus, Diana Lüftner, Oliver J. Müller, Ulrich Neudorf, Roman Pfister, Stephan von Haehling, Lorenz H. Lehmann, Johann Bauersachs, Committee for Clinical Cardiovascular Medicine of the German Cardiac Society
Published in:
Clinical Research in Cardiology
|
Issue 10/2020
Login to get access
Abstract
The acute and long-lasting side effects of modern multimodal tumour therapy significantly impair quality of life and survival of patients afflicted with malignancies. The key components of this therapy include radiotherapy, conventional chemotherapy, immunotherapy and targeted therapies. In addition to established tumour therapy strategies, up to 30 new therapies are approved each year with only incompletely characterised side effects. This consensus paper discusses the risk factors that contribute to the development of a potentially adverse reaction to tumour therapy and, in addition, defines specific side effect profiles for different treatment groups. The focus is on novel therapeutics and recommendations for the surveillance and treatment of specific patient groups.